Tony Reid, M.D., Ph.D.
Professor of Medicine
Division of Hematology-Oncology
Director of Early Phase Clinical Investigation
National Chairman, Association of American Cancer Institute's-CRI
Other academic or clinical roles:
Associate Professor of Clinical Medicine/Hematology and Oncology
Director of the Clinical Investigation Program
Co-Director of the GI Malignancy Program
University of California, San Diego. 1/2004 to 7/2010.
University of California San Diego
Moores Cancer Center
3855 Health Sciences Drive, MC-0987
La Jolla, CA 92093
FAX: 858 822-5380
|BA||Political Science and Philosophy, Grinnel College, IA||1978|
Radiation Biology, University of Iowa, IA
Biochemistry/Cancer Biology, Stanford University, CA
|MD||Stanford University, CA||1991|
|Medical Internship & Residency||Stanford University, CA||1991-1993|
|Oncology Fellow||Stanford University, CA||1993-1997|
Professor Tony Reid is a world renowned oncology physician as well as being recognized for his outstanding clinical research in colon and pancreatic cancers. He has received many accolades for his work which includes: America’s Top Doctor and Americas Top Doctor for Oncology, recognized as being in the top 1% of physicians 2011-2014; the Mary Crowly Award for Excellence in Research, and recognition for important contributions to basic and clinical research by the International Society of Gene Therapy and the Society for Interventional Radiology. He also serves on the review board of numerous journals including Nature Cancer Gene Therapy, Gene Therapy and Clinical Cancer Research.
Other Honors and Awards
Mose Schwartz Scholarship, 1975
State of Iowa Scholar, 1975
Keynote Speaker: International Interferon Meetings, 1986
Young Investigator Award: The Interferon Society, 1988
Research Award, Stanford Housestaff, 1991
Barry Research Fellowship 1996
Invited Speaker-ASCO 1998
Invited Speaker-9th International Gene Therapy Meet 2001
Invited Speaker-10th International Gene Therapy Meet 2002
Young Investigator Award. Society of Cardiology and Interventional Radiology 2002
Best of ASCO-Abstract presentation 2002
Invited Speaker- 13th International Gene Therapy Meeting 2005
Invited Speaker- Society for Gene Therapy 2007
Invited Speaker – Oncolytic Virus Conference 2009
Invited Speaker – Western Angiographic Society Meeting 2010
Invited Speaker – Memorial Sloane Kettering Grand Rounds
Invited Speaker – American Society of Pathology 2010
Invited Speaker - American Association for Study of Liver Disease, 11/2011.
Invited Speaker - MAGI conference on Clinical Research 8/12
Invited Speaker - AACI annual conference 11/2012
Invited Speaker - American Society for Clinical Oncology- 2013
Invited Speaker - Best of ASCO 2013
Invited Speaker - MAGI conference on Clinical Research 10/13
Research 1 (including basic and/or clinical research)
a. Overall focus of the research
Professor Tony Reid’s main career goals are to develop novel therapeutic approaches to diagnose, prevent, and treat tumors with gene therapy vectors. He has focused on elucidating the underlying molecular mechanism that causes cancer, focusing primarily in gastrointestinal tumors including colorectal, pancreatic, esophageal and hepatobillary cancers. His research group conducts basic science research to study disease at the molecular level and then facilitates the translation of novel scientific discoveries into practical therapeutic applications to the clinical to benefit patients. His contributions embody the scientific approach of “bench-to-bedside” medicine, promoting greater understanding of cancer and personalized disease therapies. He has a wide range of publications on the uses of new agents for the treatment of tumors and conducts a variety of clinical trials focusing on early phase therapeutics and he also uses gene therapy strategies to enhance the immune response to these tumors. He is the lead investigator and has pioneered the use of adenoviral and vaccine vectors to the treatments of cancer and is always thinking on how he can be instrumental in developing new therapies in the laboratory and how to export them to help those suffering from cancer. His speculative nature has leaded him to explore the scientific underpinnings of cancer and to make new therapeutic options available to patients by developing new clinical trials.
Clinical Trials: Currently there are many clinical trials on-going at the Moores Cancer Center. Professor Tony Reid’s innovative “thinking out of the box” philosophy of using highly tailored therapies for patients to directly deliver therapeutics specifically to the tumors has led to highly effective outcomes (see section b). One of the pioneering clinical trials for colon cancer patients with mainly liver metastases called the Selective Internal Radiation Therapy (SIRT) Trial using Yttrium-90 (Y-90) Radioactive Microspheres is a Phase II study. This successful clinical trial has been developed to treat patients whose disease has progressed after failing their first-line chemotherapy. Preliminary results so far have shown remarkable differences to patient health having stable disease and progression free survival (PFS) greater than thirty five months.
b. Past findings and achievements
i. Study Shows Liver an Excellent Target for Cancer Gene Therapy Using Viral Vectors:
A Nature Cancer Gene Therapy paper explains the scientific research where the cancer cells in the liver are excellent targets for gene therapy using adenoviral vectors, based on a fundamental new understanding of the differences between cancerous and normal liver cells. The findings showed a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast.
ii. Clinical Trial Evaluates Engineered Smallpox Vaccine as Potential Liver Cancer Killer:
As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer.
iii. AACI Clinical Research Initiative:
The Right Drug for the Right Patient: Optimizing Clinical Trials Management
iv. Spring Sprint Triathlon & Duathlon / MILLIE Award:
Dr. Reid understands that patients undergoing anti-cancer treatments are doing their “personal best” in the fight against their disease, as are athletes doing their “personal best” as they compete in sporting events such as triathlons. This event will recognize the courage, determination, and strength that cancer patients demonstrate in their daily pursuits to achieve their personal bests.
c. Current projects and their specific aims
d. Our exciting new preliminary data proved that when microspheres were administered between first and second line chemotherapy to improve the lives of patients suffering from colorectal cancer.
e. Title: A Phase II Study of Yttrium-90 Radioactive Resin Microspheres in the Treatment of Colorectal Adenocarcinoma Metastatic to the Liver After Failure of First-Line Combination Chemotherapy
1) The primary objective is the assessment of progression-free survival of patients with colorectal adenocarcinoma metastatic to the liver after failure of first line combination chemotherapy with Yttrium-90 radioactive resin microspheres.
2) Secondary objective/outcomes: The secondary objectives are the evaluation of overall survival, tumor response rates, and long-term safety of microspheres in sequence with chemotherapy.
The Selective Internal Radiation Therapy (SIRT) Trial using Yttrium-90 (Y-90) Radioactive Microspheres inclusion and exclusion criteria can be found by following the hyperlink. We are currently enrolling patients on this trial. For further details please contact us.
Research 2 --
a. Overall focus of the research:
Title: A Phase I, Open-label, Dose Escalation Study of Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
Survival of pancreatic cancer patients remains poor, and treatment with erlotinib remains one of the few agents that have demonstrated increased survival. Alternative dosing schedules for erlotinib should be explored since chronic low dose therapy fails to achieve therapeutically effective concentrations for many patients and leads to increased skin toxicity and may induce acquired resistance without significantly impacting the tumor. Therefore, higher doses given for shorter periods of exposure, similar to the dosing of most chemotherapeutic agents, may achieve more effective therapeutic doses of than chronic low dose therapy and may minimize skin toxicity observed with erlotinib.
Current findings and achievements
Preclinical studies performed in the laboratory of the principal investigator Professor Tony Reid support the hypothesis that the currently prescribed erlotinib dose in not optimal for achieving the most effective therapeutic dose range for pancreatic cancer as well as for minimizing skin toxicity. Therefore, our data suggests that acquired resistance can occur rapidly after exposure to erlotinib, and therefore, pulsed high-doses can help to maximize the clinical benefit of the use of erlotinib with having limited adverse effects. We have achieved to complete the first cohort in this clinical trial and we are showing some promising clinical data.
b. Upcoming research projects
We have many other projects in the pipeline for colon and pancreatic cancer.
Please check the following website for further information.
Hersh CL, Reid TR, Friedman R, and Stark GR. (1984) Preparation, Characterization, and use of antiserum specific for 2'-5'- Oligoadenylates. J of Biological Chemistry 259: 1727-30.
Reid TR, Hersh CL, Kerr IM, and Stark GR. (1984) Analysis of 2'-5'-Oligoadenylates in cells and tissues. Analytical Biochemistry 136: 136-41.
Kerr IM, Rice A., Roberts WK, Cayley PJ, Reid TR, Hersh CL, and Stark GM (1984) The 2'-5'-A and protein kinase systems in interferon-treated and control cells. In: Gene Expression, ed. Clark and Petersen, pp 487-499.
Reid TR, Kerr IM, and Stark GM. (1986) Identification of 2'-5'-Oligoadenylates and novel activator of ribonuclease in chicken oviduct and rat mammary gland. Prog. Clinical and Biological Research 202: 3-11.
Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, and Merigan TC. (1988) Synergistic antitumor activity with Interferon and monoclonal anti-idiotype for murine B-cell lymphoma: Mechanism of Action. J Immunology 141: 2855-60.
Reid TR, Torti FM, and Ringold GM. (1989) Evidence for two mechanisms by which tumor necrosis factor kills cells. J Biological Chemistry 264: 4583-89.
Reid TR, Race ER, Wolff BH, Friedman RM, Merigan TC, and Basham TY. (1989) Enhanced in vivo therapeutic response to interferon in mice with an in vitro-resistant B-cell lymphoma Cancer Research 49: 4163-39.
Chernajovsky Y, and Reid TR. (1990) Regulation of the human interferon-inducible 6-16 promoter in tumor necrosis-sensitive and resistant mouse cells: role of cAMP as a mediator of signal transduction. J Interferon Research 10: 627-36.
Reid TR and Ringold (1991) Resistance to Tumor Necrosis Factor Due to Defect in Arachidonic Acid Biosynthesis. J of Biological Chemistry.266: 16580-86.
Reid TR, Merigan TC, and Basham TY. (1991) Resistance to Interferon Involves DNA Methylation of Early Signaling Pathway. J of Interferon Research 12: 131-7
Reid TR, Yuen A, Catolico M; Carlson J. Impact of omeprazole on the plasma clearance of methotrexate. (1993) Cancer Chemotherapy and Pharmacology 33: 82-84.
Reid TR and Heller R. Mechanisms of tumor necrosis factor cytotoxicity and the cytotoxic signals transduced by the p75-tumor necrosis factor receptor. (1995) J of Circulatory Shock. 44:84-90, 1994.
Reid TR, Feldman B and Cleary, M. (1997) PIM-1 cooperates with E2a-pbx1 to accelerate lymphogenesis in transgenic mice. Oncogene 15, 2735.
Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S,
Maples P, Romel L, Randlev B, Reid TR, Kaye S, Kirn D. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Research (2000) 60, 6359.
Sze, DY, Reid, TR. Intraarterial treatment of metastatic gastrointestinal cancer using an E1B-deleted adenovirus. (2001) J. Vasc. Intervent. Radiol. 12: S6.
Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Dirn D. Intra-arterial administration of a replication-selective adenovirus in patients with colorectal carcinoma metasttic to the liver: a phase I trial. Nature Gene Therapy (2001) 8, 1618-26.
Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 62:6070-9
Milkes DE, Friedland S, Lin OS, Reid TR, Soetikno RM. A novel method to control severe upper GI bleeding from metastatic cancer with a hemostatic sealant: the CoStasis surgical hemostat. Gastrointest Endosc (2002) 55:735-40
Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther (2002) 9:979-86
Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma. Clin Cancer Res (2003) 9:555-61
Reid T, Sze D. New developments in medical oncology and their implications for interventional radiology. J Vasc Interv Radiol (2003) 14:279-91
Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M, Ahrar K, Gupta S, Reid TR. (2003) Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol;14:279-90.
Reid, T; Valone, F; Lipera, W; Irwin, D; Paroly, W; Sarna, G; Sreedharan, S; Keer, H; Lum, B; Scappaticci, F and Bhatnagar, A. Phase II Trial of the Histone Deacetylase Inhibitor Pivaloyloxymethyl Butyrate (Pivanex AN-9) in Advanced Non- Small Cell Lung Cancer. (2004) 45:381-6.
Thorne, S; Brooks, G, Nichols, S, Lee, Y, Eng, L and Reid, T. The Effects of Febrile Temperature on Adenoviral Infection and Replication: Implications for Viral Therapy of Cancer. J Virol. (2005) 79(1):581-91.
Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D, Hallden G. A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res. (2005) 11:351-60.
Li Y, Idamakanti N, Arroyo T, Thorne S, Reid T, Nichols S, VanRoey M, Colbern G, Nguyen N, Tam O, Working P, Yu DC. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models. Clin Cancer Res. (2005) 11:8845-55
Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Nature Cancer Gene Therapy. (2005) 12:673-81.
Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR. Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.
Nature Cancer Gene Therapy (2007) 14:139-50.
Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol. (2007) 25:3544-6.
Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol. (2008) 4:483-500.
Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther. (2008) 10:371-9
Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, Seymour L, Rubanyi GM, Harkins RN, Hermiston TW. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE. (2008) 3(6):e2409.
Reid TR. Fighting Fire with Fire: Effects of Oncolytic Virotherapy on Underlying Viral Hepatitis in Hepatocellular Carcinoma. Molecular Therapy (2008) 16, 1521–1523
Costantini CL, Reid TR, Bouvet M. Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer. Hepatogastroenterology. (2009) 56:645-9.
Chang JF, Chen PJ, Sze DY, Reid T, Bartlett D, Kirn DH, Liu TC. Oncolytic virotherapy for advanced liver tumours. J Cell Mol Med. 2009 Jul;13(7):1238-47.
Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 1;27(34):5763-71. Epub 2009 Nov 2.
Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):85-9. Epub 2010 May 15.
Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, Tawfik H. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010 Sep;21(9):1119-28.
Hedjran F, Shantanu K, Reid T. Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b. Cancer Gene Ther 18: 717-723; advance online publication, August 5, 2011
Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2011 Dec;68(6):1507-16. Epub 2011 Apr 17.
Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography. Hum Gene Ther. 2012. 23:91-7. Epub 2011 Oct 14.
Chang KJ, Reid T, Senzer N, Swisher S, Pinto H, Hanna N, Chak A, Soetikno R. Phase I evaluation of TNFerade Biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointest Endosc. 2012 75:1139-46. Epub 2012 Apr 18
Oronsky BT, Scicinski JJ, Reid T, Knox S. Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review. Translational Oncol. 2012 5:133-40. Epub 2012 Jun 1.
Oronsky BT, Reid T, Knox SJ, Scicinski JJ. The scarlet letter of alkylation: a mini review of selective alkylating agents. Transl Oncol. 2012;5(4):226-9.
Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013 1;31(7):886-94.
Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19(3):329-36.
Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, Rado TA, McGee PJ, Richards DA, Tarazi J, Rosbrook B, Kim S, Cartwright TH. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study. Cancer. 2013 Apr 19. [Epub ahead of print]
Larson C, Mendez N, Reid T. Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system. Mol Ther. 2013;21(5):922-3.
Paulmurugan R, Oronsky B, Brouse CF, Reid T, Knox S, Scicinski J. Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm. Theranostics. 2013 May 25;3(6):437-47.
Sze DY, Reid TR, Rose SC. Oncolytic virotherapy. J Vasc Interv Radiol. 2013 Aug;24(8):1115-22.
Reid T. Reintroduction of Imatinib in GIST. J Gastrointest Cancer. 2013 Aug 7. [Epub ahead of print]